Stock Evaluator: Bluejay Diagnostics, Inc. (BJDX)

Bluejay Diagnostics, Inc. BJDX

$0.93 0.05 5.77%
July 30, 2026 4:00:00 PM EST November 10, 2021 Volume: 192,180
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Health Care Equipment & Supplies

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Bluejay Diagnostics, Inc. operates as a medical diagnostics company. It offers Symphony technology platform which consists of an analyzer and single-use protein detection cartridges that are designed to provide measurements of key diagnostic biomarkers found in blood; and Symphony analyzer used to orchestrate sample processing of whole blood, plasma, serum, etc., biomarker isolation, and immunoassay preparation using non-contact centrifugal force. The company also develops Symphony IL-6 tests for the monitoring of disease progression in critical care settings. In addition, it develops additional tests for Symphony, such as tests for myocardial infraction and congestive heart failure, as well as other tests using the Symphony platform. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.

Commentary & Analysis


Financial Summary

Share Statistics BJDX Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $1.0 $334.8 1%
Shares Out (Mil) 1.0 41.7 4%
Institutional Ownership 77.2% 77.3% 47%
Float (Mil) 0.9 34.7 2%
Beta 0.87 0.86 52%
Avg Daily Volume (000s) 568 266 61%
Price Change
(52-week)
(85.3%) 60.7% 5%
Growth BJDX Industry
Median
Percentile
(All Stocks)
Sales (5yr) na 11.8% na
Net Income (5yr) (41.5%) (5.8%) 9%
EPS (5yr) na 10.7% na
Dividends (5yr) na 0.0% na
Cash Flow (5yr) na (16.1%) na
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates na na na
Current EPS na na na
Month Ago EPS na na na
# Rev Up na na na
# Rev Down na na na
Three Months Ago EPS na na na
Year/Year Chg na na na
Financials BJDX Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) na $152 na
Net Income (TTM) (Mil) ($7) ($11) 32%
EPS (TTM) ($10.450) ($0.500) 4%
Operating Cash Flow (TTM) (Mil) ($7) ($2) 23%
Net Cash Flow (TTM) (Mil) na $1 na
Long-Term Debt (Q1) (Mil) $0 $22 0%
Enterprise Value (Q1) (Mil) ($2) $304 3%
Valuation BJDX Industry
Median
Percentile
(All Stocks)
P/B 0.23 2.88 4%
P/E na 30.5 na
Dividend Yield na 0.0% na
PEG (5yr hist) na 1.9 na
Ratios BJDX Industry
Median
Percentile
(All Stocks)
Gross Margin na 59.1% na
Net Margin na (7.7%) na
ROA (126.9%) (13.7%) 4%
ROE (171.6%) (15.9%) 5%
Liabilities to Assets 25.3% 44.9% 17%
F-Score 4 4 na

Bluejay Diagnostics, Inc. did not pass any screens on 7/30/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors